Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis

By K. Saag, J. Petersen, M. Brandi, A. Karaplis, M. Lorentzon, T. Thomas, J. Maddox, M. Fan, P. Meisner, A. Grauer. New England Journal of Medicine, 2017

1,237 citations recorded by the source corpus.

Subfields: Oncology, Orthopedics and Sports Medicine

View Paper: https://www.semanticscholar.org/paper/777e63ff5360707725c8ae701182d9ae1dd31d6f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. S. Angers
2. Z. Steinhart

Citations in the corpus

• The clinician’s guide to prevention and treatment of osteoporosis (2022, background): “In the ARCH study, high-risk postmenopausal women had significantly fewer fractures when treated with romosozumab than with alendronate (48% fewer new vertebral fractures, 19% fewer non-vertebral fractures, and 38% fewer hip fractures) for 12 months [197].”
• Wnt signaling in development and tissue homeostasis (2018, background): “…companies have developed anti-SOST antibodies to activate endogenous Wnt-β -catenin circuitries in bone tissues, and these have been shown in clinical trials to augment bone mass density and prevent fractures (Glorieux et al., 2017; Recker et al., 2015; Saag et al., 2017; Williams, 2017).”